Next generation reagents for mass cytometry and imaging mass cytometry

用于质谱流式分析和成像质谱流式分析的下一代试剂

• 批准号: 566946-2021
• 负责人: Winnik, MitchellMA
• 金额: $ 6.27万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=748336
• 关键词: Next; generation; reagents; mass; cytometry

The purpose of this project is to develop better tools to help scientists in biology and the biomedical area study biological samples. Mass cytometry is a technology developed in Canada and manufactured by Fluidigm Canada in Markham ON that enables these scientists to measure and quantify many biomarkers simultaneously on cells and issue samples. Biomarkers are proteins and other biomolecules expressed on the surface of cells or inside the cells. They convey information about cell type, behavior and function as well as the disease state of a cell. Mass cytometry employs reagents based on antibodies labeled with heavy metal isotopes to detect proteins and other biomarkers expressed on individual cells. In mass cytometry, the cells are injected into the plasma torch of an atomic mass spectrometer, where the cells are vaporized, atomized and ionized to generate a cloud of the metal ions that were attached to each cell. These ions are then analyzed by mass spectrometry. Mass cytometry enables one to examine individual cells at high throughput (up to 1000 cells/sec). Its greatest strength is that it can simultaneously measure many more biomarkers per cell than flow cytometry, which employs fluorescent reagents. In current technology, one can measure ~50 biomarkers per cell at 500 to 1000 cells per second. We propose to create new reagents that will increase this number to more than 80 biomarkers per cell. To identify proteins expressed at very low levels, we will create a different set of reagents that will increase signal intensity by 10 to 100 times. This new technology will enhance our ability to study biological and disease processes, and may in the future enhance early diagnosis of disease.

该项目的目的是开发更好的工具来帮助生物学和生物医学领域的科学家研究生物样本。质谱流式细胞仪是加拿大开发的一项技术，由位于安大略省万锦市的 Fluidigm Canada 制造，使这些科学家能够同时测量和量化细胞上的许多生物标志物并发出样本。生物标志物是在细胞表面或细胞内部表达的蛋白质和其他生物分子。它们传达有关细胞类型、行为和功能以及细胞疾病状态的信息。质谱流式细胞术使用基于重金属同位素标记的抗体的试剂来检测单个细胞上表达的蛋白质和其他生物标志物。在质谱流式分析中，细胞被注入原子质谱仪的等离子炬中，细胞在其中被汽化、原子化和电离，以产生附着在每个细胞上的金属离子云。然后通过质谱分析这些离子。 质谱流式细胞仪能够以高通量（高达 1000 个细胞/秒）检查单个细胞。其最大的优势在于，与使用荧光试剂的流式细胞术相比，它可以同时测量每个细胞更多的生物标志物。在当前技术中，人们可以以每秒 500 至 1000 个细胞的速度测量每个细胞约 50 个生物标志物。我们建议创造新的试剂，将每个细胞的生物标志物数量增加到 80 多个。为了识别表达水平非常低的蛋白质，我们将创建一组不同的试剂，将信号强度提高 10 至 100 倍。这项新技术将增强我们研究生物和疾病过程的能力，并可能在未来增强疾病的早期诊断。